Boehringer Ingelheim’s Spiriva Respimat improves outcomes in diverse patient group
Boehringer Ingelheim touted studies from a Phase III program which showed that adding tiotropium Respimat, or Spiriva Respimat, improved breathing across a diverse population of asthma patients.
The group included patients who experienced uncontrolled asthma symptoms despite the use of another daily maintenance therapy. Adding the company’s drug improved lung function and asthma symptom control in kids and adolescents compared to placebo, independent of the type of allergic asthma.
The company also reported that the addition of Spiriva Respimat improved airflow obstruction in adults with symptomatic asthma compared to placebo, regardless of body mass index.
“These new analyses add to the wealth of evidence from the large-scale UniTinA-asthma clinical trial program to show tiotropium Respimat is effective in a broad range of patients with symptomatic asthma, including those with allergies or a high BMI, which may make their symptoms more difficult to manage,” Jennifer Haddon, global medical advisor for the company’s respiratory biz, said in prepared remarks. “Of those people already on asthma treatment, almost half still experience symptoms, highlighting the need for better management. These data underline the commitment of Boehringer Ingelheim to advancing our understanding of which patients may benefit most from our medicines.”
NEXT: Theravance Biopharma, Mylan report data from pivotal late stage revefenacin trials
